**Supplementary material - Do commonly administered drugs inadvertently modify the progression of spinal cord injury? A systematic review**

Table of Contents

[Figures 2](#_Toc151128537)

[Figure S1 2](#_Toc151128538)

[Figure S2 3](#_Toc151128539)

[Tables 4](#_Toc151128540)

[Table S1. 4](#_Toc151128541)

[Table S2. 8](#_Toc151128542)

[Table S3. 16](#_Toc151128543)

[Table S4. 17](#_Toc151128544)

[Table S5. 20](#_Toc151128545)

[Table S6. 21](#_Toc151128546)

[Table S7. 22](#_Toc151128547)

Figures

A graph of different sizes and colors

Description automatically generated with medium confidence

Figure S1

Publication trends over time. A. General overview of the number of experiments included per year of publication. B. Details of repartition of species used in animal models over time. C. Details of repartition of sex in animal models over time.

A graph of a drug

Description automatically generated with medium confidence

Figure S2

Details of the mixed drug effects reported for drugs studied in at least five experiments. Circle size is proportional to the number of experiments reporting the effect of interest. Circles are colored proportionally to the frequency that the effect of interest represents among all experiments studying the drug of interest.

Tables

Table S1.

List of drugs included in analysis. Shaded rows highlight drugs tested in combination.

|  |  |
| --- | --- |
| **Drug(s) tested** | **Number of publications** |
| acetylcysteine | 5 |
| acetylsalicylic acid | 1 |
| albumin | 3 |
| aluminum | 1 |
| amiloride | 4 |
| amphetamine | 2 |
| atorvastatin | 9 |
| azithromycin | 2 |
| baclofen | 1 |
| botulinum toxin | 1 |
| bupivacaine | 1 |
| buspirone | 2 |
| calcitriol | 2 |
| carbidopa levodopa | 1 |
| carvedilol | 2 |
| ceftriaxone | 2 |
| ceftriaxone + acetylcysteine | 1 |
| celecoxib | 1 |
| chlorpromazine | 1 |
| citalopram | 1 |
| clonidine | 1 |
| clopidogrel | 1 |
| cyproheptadine | 3 |
| dantrolene | 4 |
| dapsone | 1 |
| darbepoetin | 1 |
| dexamethasone | 15 |
| dexamethasone + estrogen | 1 |
| dexamethasone + melatonin | 1 |
| dexmedetomidine | 2 |
| diclofenac | 1 |
| epinephrine | 1 |
| epinephrine + nitroprusside | 1 |
| epoetin | 4 |
| epoietin | 2 |
| escitalopram | 2 |
| estradiol | 18 |
| estradiol + testosterone | 1 |
| estrogen | 3 |
| ethanol | 2 |
| ethanol + isoflurane | 1 |
| ethanol + ketamine + pentobarbital | 1 |
| etomidate | 1 |
| etomidate + epoietin | 1 |
| etomidate + methylprednisolone | 1 |
| ezetimibe | 1 |
| ezetimibe + simvastatin | 1 |
| fenofibrate | 1 |
| fentanyl + nitrous oxide | 1 |
| fentanyl + nitrous oxide + naloxone | 1 |
| fluoxetine | 4 |
| fluoxetine + vitamin c | 1 |
| folic acid | 2 |
| folic acid + nitrous oxide | 1 |
| gabapentin | 1 |
| glibenclamide | 1 |
| glucosamine | 1 |
| glutamine | 2 |
| heparin | 2 |
| hydralazine | 1 |
| ibuprofen | 4 |
| immune globulin | 3 |
| indomethacin | 3 |
| ketoprofen | 1 |
| levocarnitine | 1 |
| levodopa | 2 |
| lidocaine | 2 |
| liothyronine | 1 |
| lithium | 8 |
| magnesium | 2 |
| magnesium + methylprednisolone | 1 |
| magnesium chloride + polyethylene glycol | 3 |
| magnesium sulfate | 5 |
| magnesium sulfate + polyethylene glycol | 2 |
| mannitol | 3 |
| melatonin | 21 |
| meloxicam | 1 |
| metformin | 5 |
| methotrexate | 3 |
| methylprednisolone | 81 |
| methylprednisolone + acetylcysteine | 1 |
| methylprednisolone + epoietin | 1 |
| methylprednisolone + magnesium chloride + polyethylene glycol | 1 |
| methylprednisolone + magnesium sulfate | 1 |
| methylprednisolone + melatonin | 1 |
| methylprednisolone + methotrexate | 1 |
| methylprednisolone + mycophenolate | 1 |
| methylprednisolone + pregabalin | 1 |
| methylprednisolone + rosuvastatin | 1 |
| methylprednisolone sodium succinate | 23 |
| methylprednisolone sodium succinate + aminocaproic acid | 1 |
| methylprednisolone sodium succinate + dantrolene | 1 |
| methylprednisolone sodium succinate + vitamin c | 1 |
| mexiletine | 2 |
| minocycline | 22 |
| minocycline + tacrolimus | 1 |
| modafinil | 1 |
| montelukast | 2 |
| morphine | 6 |
| morphine + minocycline | 1 |
| morphine sulfate | 2 |
| mycophenolate | 1 |
| naloxone | 24 |
| naltrexone | 1 |
| naproxen | 2 |
| niacin | 1 |
| nicotine | 1 |
| nifedipine | 1 |
| nitrous oxide | 1 |
| omega 3 | 5 |
| oxandrolone | 1 |
| pentobarbital | 1 |
| phenytoin | 4 |
| pioglitazone | 3 |
| plasma | 1 |
| platelets | 1 |
| polyethylene glycol | 10 |
| prednisolone | 1 |
| prednisone | 1 |
| pregabalin | 2 |
| progesterone | 3 |
| progesterone + vitamin d | 1 |
| propofol | 2 |
| selegiline | 1 |
| sevoflurane | 1 |
| simvastatin | 8 |
| sitagliptin | 1 |
| tacrolimus | 8 |
| tadalafil | 1 |
| tamoxifen | 8 |
| testosterone | 2 |
| theophylline | 1 |
| thiopental | 1 |
| thiopental + naloxone | 1 |
| topiramate | 3 |
| tramadol | 1 |
| trifluoperazine | 1 |
| ubiquinone | 1 |
| valproic acid | 10 |
| vitamin c | 3 |
| vitamin c e | 1 |
| vitamin d | 2 |
| vitamin e | 2 |
| zinc | 4 |

Table S2.

Neurological and functional outcomes for animal studies included in the review

|  |  |  |
| --- | --- | --- |
| **Category** | **Harmonised assessment name** | **Assessment name as reported in literature** |
| locomotion | BBB | Basso Beatie Brenahan (BBB) locomotor scale |
|  |  | Basso Beattie and Bresnahan (BBB) rating scale |
|  |  | Basso Beattie Brenahan (BBB) locomotor scale |
|  |  | Basso-Beatie-and Bresnahan (BBB) scale |
|  |  | Basso-Beatie-Bresnahan (BBB) scale |
|  |  | BBB |
|  |  | BBB hind limb locomotor rating scale |
|  |  | BBB lcoomotor score |
|  |  | BBB locomoter scale |
|  |  | BBB locomotor rating scale |
|  |  | BBB locomotor scale |
|  |  | BBB locomotor scale (canine) |
|  |  | BBB locomotor scale (modified) |
|  |  | BBB locomotor scale (mouse version adapted to local protocol) |
|  |  | BBB locomotor scale (mouse version) |
|  |  | BBB locomotor score |
|  |  | BBB Locomotor test |
|  |  | BBB locomotor test |
|  |  | BBB method |
|  |  | BBB rating scale |
|  |  | BBB scale |
|  |  | BBB score |
|  |  | BBB scoring |
|  |  | BBB scoring scale |
|  |  | BBB scoring system |
|  |  | BBB subscores |
|  |  | BBB subscoring |
|  |  | BBB test |
|  |  | modified BBB hindlimb locomotor scale |
|  |  | modified murine BBB hindlimb locomotor rating scale |
|  |  | modified murine BBB hindlimb locomotor-rating scale |
|  |  | modified murine BBB scale |
|  |  | straight alley BBB |
|  | BMS | Basso mouse scale |
|  |  | Basso Mouse Scale (BMS) |
|  |  | Basso Mouse scale (BMS) |
|  |  | Basso mouse scale (BMS) |
|  |  | BBB locomotor scale (mouse version adapted to local protocol) |
|  |  | BMS |
|  |  | BMS scale |
|  |  | BMS score |
|  | beam walk test | beam walk |
|  |  | beam walk test |
|  |  | beam walk tests |
|  |  | Beam walking test |
|  |  | narrow beam crossing test |
|  |  | narrow beam test |
|  |  | narrow beam test |
|  |  | narrow beam-crossing test |
|  |  | tapered beam test |
|  |  | tapered beam walk test |
|  | footprint analysis | foot print analysis (fine motor control) |
|  |  | footprint analysis |
|  |  | footprint analysis (fine motor control) |
|  |  | footprint recording |
|  | gait analysis | 2D hindlimb kinematics during weight-supported treadmill locomotion |
|  |  | 3D kinemtic data |
|  |  | angulograms (quality and range of motion) |
|  |  | base of support |
|  |  | catwalk gait analysis |
|  |  | CatWalk gait analysis |
|  |  | Catwalk-automated quantitative gait analysis |
|  |  | Gait analysis |
|  |  | gait analysis (DigiGait) |
|  |  | gait analysis with CatWalk XT 10.6 multivariate system |
|  |  | gait recording |
|  |  | hind limb gait |
|  |  | kinematic analysis with the CatWalk gait analysis system |
|  |  | kinematic profile |
|  |  | locomotion analsyis with MotoRater apparatus |
|  |  | locomotor analysis with MotoRater apparatus |
|  |  | toe spread index |
|  | grid walking test | grid walk test |
|  |  | gridwalk test |
|  |  | grid walking test |
|  |  | grid-walking test |
|  |  | horizontal grid walking |
|  |  | ability to traverse wire grid |
|  |  | horizontal grid |
|  |  | grid footfalls |
|  |  | grid walking |
|  | inclined plane test | angled plane score |
|  |  | incline plane score (IPS) |
|  |  | incline plane test method |
|  |  | inclined plane |
|  |  | inclined plane assessemnt |
|  |  | inclined plane assessment |
|  |  | inclined plane method |
|  |  | inclined plane method of Rivlin and Tator |
|  |  | inclined plane score |
|  |  | inclined plane score (IPS) |
|  |  | inclined plane task |
|  |  | inclined plane technique |
|  |  | inclined plane test |
|  |  | inclined plane test (modified Rivlin's method) |
|  |  | inclined plane test method |
|  |  | inclined plane tests |
|  |  | inclined plate test |
|  |  | inclined test |
|  |  | rivlin and tator's inclined plane test |
|  |  | Rivlin inclined plane test |
|  | ladder walk test | 45 degrees ladder walk test |
|  |  | footfalls |
|  |  | horizontal ladder |
|  |  | horizontal ladder crossing test |
|  |  | horizontal ladder task |
|  |  | horizontal ladder test |
|  |  | horizontal ladder test (adapted to local protocol) |
|  |  | horizontal ladder walk test |
|  |  | horizontal ladder walk tests |
|  |  | ladder walk |
|  |  | ladder walk test |
|  |  | ladder walk tests |
|  |  | walk on ladder |
|  | locomotor (other) | activity box |
|  |  | activity box test (ABT) |
|  |  | activity measures |
|  |  | categorisation of walking ability (paraplegia/poor walker/walker) |
|  |  | clinical grading |
|  |  | clinical motor exam (Drummond and Moore) |
|  |  | Drummond and Moore criteria |
|  |  | Drummond and Moore motor function score |
|  |  | Eugene D Means and Douglas K Anderson's motility score |
|  |  | Forelimb locomotor scale |
|  |  | grading of motor disturbance (Drummond and Moore scale) |
|  |  | gross motor activity (activity box) |
|  |  | hind limb motor function score (MFS) |
|  |  | motor capacity |
|  |  | motor deficit index |
|  |  | motor function |
|  |  | motor function scale |
|  |  | motor function scale (Farooque) |
|  |  | motor performance on rotarod |
|  |  | neurological function (walking status) |
|  |  | neurological scores (locomotor status) |
|  |  | Open field test |
|  |  | open field test |
|  |  | porcine thoracic behavior scale |
|  |  | presence/absence of hindlimb paralysis |
|  |  | recovery index (mobility) |
|  |  | rotarod |
|  |  | rotarod locomotor function test |
|  |  | spontaneous movement |
|  |  | unprompted walking motor score |
|  | swimming | swimming performance |
|  |  | swimming test |
|  | Tarlov scale | five-point modified Tarlov scale |
|  |  | hind limb motor function (modified Tarlov) |
|  |  | hind-limb motor-function according to Tarlov |
|  |  | modified five-point scale developed by Tarlov |
|  |  | modified Tarlov method |
|  |  | modified Tarlov rating system |
|  |  | modified Tarlov scale |
|  |  | modified Tarlov scale |
|  |  | modified Tarlov score |
|  |  | modified Tarlov scoring system |
|  |  | modified tarlov's grading scale |
|  |  | modified Tarlov's motor scale |
|  |  | motor function (modified Tarlov scale) |
|  |  | Tarlov motor scale |
|  |  | Tarlov scale |
|  |  | Tarlov scoring |
|  |  | Tarlov scoring system |
|  |  | Tarlov's scoring system |
|  |  | Tarlow scale |
| forelimb function | grip strength | grip strength meter |
|  |  | grip strength task |
|  | reaching or retrieval | directed forepaw reaching (DFR) |
|  |  | grasping test (food retrieval) |
|  |  | modified Montoya's staircase test |
|  |  | Montoya staircase reaching |
|  |  | staircase test |
|  |  | vermicelli handling test |
|  | rearing | cylinder rearing test |
|  |  | cylinder test (forelimb assymetry) |
|  |  | open field test (rearing) |
|  |  | paw placement |
|  |  | rearing |
| sensory and pain | mechanical reactivity | cutaneus trunchi muscle reflex |
|  |  | cutaneus trunci muscle (CTM) reflex |
|  |  | foot withdrawal under mechanical stimuli |
|  |  | girdle test |
|  |  | localisation reflex |
|  |  | mechanical reactivity |
|  |  | mechanical reactivity (von Frey) |
|  |  | mechanical sensitivity |
|  |  | mechanical sensitivity (von Frey filaments) |
|  |  | proprioception |
|  |  | proprioceptive placing response |
|  |  | response to mechanical stimuli |
|  |  | sensory function (paw withdrawal) |
|  |  | sensory function (von Frey filaments) |
|  |  | sensory testing (forelimb withdrawal under mechanical stimulation) |
|  |  | tactile capacity |
|  |  | tactile reactivity |
|  |  | tactile reactivity (girdle test) |
|  |  | tactile sensory test with Von Frey filaments |
|  |  | tape sensing and removal test |
|  |  | touch-evoked agitation |
|  |  | vocal/sensory score |
|  |  | vocalization threshold to mechanical pressure |
|  |  | Von Frey test |
|  |  | von Frey test |
|  |  | Von Frey testing |
|  | other reflexes | physiological reflexes |
|  |  | test of hindlimb reflexes |
|  | pain | gross neurologic examination |
|  |  | hindpaw pinprick sensory threshold test |
|  |  | hindpaw pinprick sensory treshold test |
|  |  | hindpaw withdrawal threshold for mechanical allodynia |
|  |  | hindpaw withdrawal treshold for mechanical allodynia |
|  |  | mechanical allodynia |
|  |  | mechanical allodynia testing |
|  |  | painful stimulus by pinching of rat tail |
|  |  | paraplegia status (tail pinch) |
|  |  | pinprick |
|  |  | purposeful response to paw pinch |
|  |  | Rat Grimace Scale |
|  |  | response to noxious stimulation |
|  |  | sensitivity to pain |
|  |  | Von Frey test of mechanical allodynia/hyperalgesia |
|  | thermal reactivity | acetone drop test |
|  |  | Hargreave's test |
|  |  | hot-water test |
|  |  | neuropathic pain evaluation [acetone drop test and thermal hyperalgesia] |
|  |  | nociceptive reactivity (thermal shock threshold tested through tail-flick test) |
|  |  | nociceptive reactivity (thermal) |
|  |  | sensory blockade (heat) |
|  |  | sensory function (hot plate/cold stimulation) |
|  |  | tail flick test |
|  |  | tail-flick test |
|  |  | thermal hyperalgesia |
|  |  | thermal reacitivity (standard hot-plate test/cold stimulation) |
|  |  | thermal reactivity |
|  |  | thermal sensitivity |
|  |  | Thermal Sensitivity |
|  |  | thermal sensitivity (tail flick) |
|  | toe spread test | toe spread test |
|  |  | toe-spread test |
|  |  | toe spread tests |
|  |  | toe spread |
|  |  | toe spread reflex |
| electrophysiology | electrophysiology (other) | activity in hemidiaphragm and phrenic nerve ipsilateral to hemisection |
|  |  | assessment of H-reflex |
|  |  | compound action potential (CAP) recording |
|  |  | compound action potentials |
|  |  | EMG recordings |
|  |  | frequency dependent depression (FDD) of H-reflex |
|  |  | H-reflex analysis |
|  |  | sciatic nerve stimulation |
|  | motor evoked potentials | corticomotor evoked potentials |
|  |  | corticomotor evoked potentials (CMEPs) |
|  |  | evoked muscle responses (EMR) |
|  |  | evoked potential test (MEP) |
|  |  | motor evoked potential |
|  |  | motor evoked potential (MEP) |
|  |  | motor evoked potentials |
|  |  | motor evoked potentials (MEP) |
|  |  | motor evoked potentials recording |
|  |  | Motor-evoked potential (MEP) |
|  |  | motor-evoked potential (MEPs) |
|  |  | motor-evoked potentials (MEPs) |
|  |  | rubrospinal motor evoked potentials (rMEP) |
|  |  | spinal motor–evoked potentials (sMEPs) |
|  | somatosensory evoked potentials | cortical somatosensory evoked potentials |
|  |  | cortico somatosensory evoked potentials (CSEP) |
|  |  | evoked potentials measured |
|  |  | SEPs |
|  |  | somatosensory evoked potential (SEP) |
|  |  | somatosensory evoked potential (SEPs) |
|  |  | somatosensory evoked potential (SSEP) |
|  |  | somatosensory evoked potentials |
|  |  | somatosensory evoked potentials (SEP) |
|  |  | somatosensory evoked potentials (SEPs) |
|  |  | somatosensory evoked potentials (SSEP) |
|  |  | somatosensory evoked potentials (SSEPs) |
|  |  | somatosensory evoked responses (SER) |
|  |  | somatosensory-evoked potential (SEPs) |
|  |  | somatosensory-evoked potentials (SEPs) |
|  |  | somotosensory evoked potentials (SSEP) |
|  |  | SSEP |
|  |  | SSEPs |
|  | spinal cord evoked potentials | spinal cord evoked potential recording |
|  |  | spinal cord evoked potentials |
|  |  | spinal cord evoked potentials (SCEPs) |
|  |  | spinal evoked potentials (SEP) |
| other | composite scores | motor sensory deficit index (MSDI) |
|  |  | neurologic scores (motor and sensory deficit) |
|  |  | sensory and motor evaluations (paraplegia status) |
|  | Gale scale | combined behavioral score (Gale scale/CBS) |
|  |  | functional deficits scoring |
|  |  | Gale scale |
|  |  | gale scale |
|  |  | modified Gale scale |
|  |  | motor function scale (modified Gale) |
|  |  | motor function scale according to Gale et al. (1985) |
|  |  | motor function score (modified Gale) |
|  |  | overall hindlimb impairment (modified CBS) |
|  | hindfoot bar grab test | hindfoot bar grab test |
|  |  | hindfoot bar grab tests |
|  | micturition | bladder function |
|  |  | micturition (voiding behaviour) |
|  | spinal cord blood flow | spinal cord blood flow |
|  |  | spinal cord blood flow (SCBF) |

Table S3.

Neurological and functional outcomes for human studies included in the review

|  |  |  |  |
| --- | --- | --- | --- |
| **Category** | **Assessment name reported** | **Assessment** | |
| neurological | neurological (motor and sensory) | | marked recovery (combination of improvement in AIS grade and walking function) |
|  |  | | pinprick, light touch, motor function scale |
|  |  | | ASIA motor and sensory scores |
|  |  | | ASIA scale: motor and sensory composites |
|  |  | | ASIA motor score, ASIA sensory score |
|  |  | | motor score; light touch (LT) and pin prick (PP) scores |
|  | neurological (motor) | | ASIA motor score |
|  |  | | ASIA Motor score |
|  |  | | ISNCSCI motor score |
|  |  | | strength |
|  |  | | discharge motor score |
|  | neurological (other) | | improvement to level of injury (change in segment to more caudal location) |
|  | injury severity | | marked recovery (combination of improvement in AIS grade and walking function) |
|  |  | | improvement in ASIA scale |
|  |  | | ASIA impairment score and grade |
|  |  | | ASIA grade |
| functional | functional (general) | | Spinal Cord Independence Measure |
|  |  | | Functional Independence Measure |
|  |  | | London Handicap scale |
|  |  | | Short Form 36 Questionnaire |
|  |  | | FIM discharge score |
|  | functional (mobility) | | FIM motor score |
|  | functional (mobility and general) | | Walking Index for SCI II (WISCI II), Spinal Cord Independence Measure II (SCIM II) |
|  | functional (mobility and spasticity) | | overground walking performance; treadmill walking performance |
|  |  | | spastic reflexes (modified Ashworth scale); walking function |
| electrophysiology |  | | EMG |

Table S4.

Variables extracted from studies included for analysis

|  |  |  |
| --- | --- | --- |
|  | **Variable extracted** | **Details** |
| General information | Person in charge | Person in charge of the data extraction |
| Authors | First author et al |
| Year | Year of publication |
| Title | Full title |
| DOI or PMID | Unique identifier |
| Language | Language of the main text |
| Inclusion/exclusion | Included/excluded | Included or excluded |
| Reason for exclusion | Primary reason of exclusion |
| Reason for exclusion | Reason of exclusion if primary reason of exclusion is "out of scope" |
| Reason for exclusion (description) | Description of the reason of exclusion |
| Classification | Data collection | Prospective or retrospective (human studies only) |
| Analysis | Prospective or retrospective (human studies only) |
| Study population | Species | Species studied among humans, mice, rats, dogs, cats, fish, lampreys, sheep, rabbits, guinea pigs, others |
| Species information | Information about subspecies used |
| Count, n | Total number of subjects reported |
| Count, n control group | Number of subjects in control group (included in analysis) |
| Count, n died in control group | Number of subjects assigned to control group not included in analysis due to premature death |
| Count, n excluded in control group | Number of subjects assigned to control group not included in analysis for other reasons |
| Count, n treatment group | Number of subjects in treatment group (included in analysis) |
| Count, n died in treatment group | Number of subjects assigned to treatment group not included in analysis due to premature death |
| Count, n excluded in treatment group | Number of subjects assigned to treatment group not included in analysis for other reasons |
| Comment on counts | Details on counts, especially when total control + total treament do not add to total n |
| Sex (n, ratio, percentage) | Information about sex of subjects as reported in the publication |
| Sex | One option among female, male, mixed and not reported |
| Sex (%, male) | % male included in the study |
| Age [days, months, years] | Information about age of subjects as reported in the publication |
| Age (mean) | Mean age (when applicable) |
| Age (SD) | SD age (when applicable) |
| Age (min) | Minimum age (when age range reported) |
| Age (max) | Maximum age (when age range reported) |
| Age (units) | Age units used among days, weeks, months and years |
| Age (comments) | Comment on age information, one option among not reported, adult, young, for publication not reporting precise age included |
| Weight [g, kg, pounds] | Information about weight of subjects as reported in the publication |
| Weight (mean) | Mean weight (when applicable) |
| Weight (SD) | SD weight (when applicable) |
| Weight (min) | Minimum weight (when weight range reported) |
| Weight (max) | Maximum weight (when weight range reported) |
| Weight (unit) | Weight units among g, kg, pounds |
| Weight (comments) | Comment on weight information (e.g., not reported) |
| Injury characteristics (level, severity) | Information about injury characteristics included level and severity as reported in the publication |
| Injury level | Level of injury (unique level or range for animal studies, number of subject per level or category for human studies) |
| Injury severity | Injury severity among moderate, mild, severe, complete, incomplete, paraplegia, tetraplegia, not reported, mixed and moderate-severe |
| Injury mechanism | Injury mechanism among contusion, compression, distraction, dislocation, transection, ischemia, trauma and others. Note this classification mainly applies for animal models, injury mechanism reported may differ in human studies |
| Injury mechanism (details) | Details on injury mechanisms (e.g., height and weight used in contusion injuries, time before repurfusion in ischmic injuries etc) |
| Duration of SCI | Duration of SCI before euthanasia (animals) or duration of SCI before inclusion in study (human) |
| Drug information | Drug(s) | Drug(s) studied in the publication |
| Drug name harmonized | Drug name harmonized based on [Bourguignon et al., 2022] |
| MP used as main drug? | Yes or no, for publication investigation methylprednisolone and methylprednisolone sodium succinate only (assess if the drug was the main drug of interest or used as positve control) |
| Dose (absolute dose or mg/kg) | Dose given |
| Time (minutes pre-injury, minutes post-injury) | Timing of start of treatment compared to injury |
| Duration of treatment | Duration of treatment |
| Timing (e.g., BID, PID) | Frequency of treatment |
| Route | Route used for drug administration |
| Route (comment when multiple) | Comments on the route used |
| Neurological and functional assessment | What was assessed? (e.g., neurological, functional recovery, spasticity, walking function, electrophysiology) | Type of neurological/functional assessment (broad categories) |
| Name/type of asessement | Neurological/functional assessments as named in the publication |
| Name of assessment harmonised | Neurological/functional assessments' names harmonised as described in Table S3 |
| Details on assessement | Details on assessments as described in the publications |
| Timing of assessement | Time of assessment with respect to the injury |
| Assessment on day 28 (yes/no) | Whether subjects were assessed at day 28 after injury (applies to experiments testing methylprednisolone and methylprednisolone sodium succinate only) |
| Was observer blinded? | Options among no, yes and not reported |
| Drug effect on functional assessment | Options qualifying effects among positive, negative, no effect, mixed (assessment), mixed (dosage), mixed (timing), mixed (regime), no stats, mixed (stats/no stats), mixed (assessment) + mixed (timing), not reported, mixed (dosage) + mixed (timing), mixed (dosage) + mixed (assessment), mixed (dosage) + mixed (regime), mixed (assessment) + mixed (regime) |
| Drug effect on functional assessment (details) | Details on the effects reported allowing to categorize the effects in the previous column |
| Neuroanatomical assessments | What was assessed? (e.g., histological measures, cavitity measures, ect ) | Type of histological assessment (broad categories) |
| Name/type of asessement | Histology assessments as named in the publication |
| Timing of assessement | Time of assessment with respect to the injury |
| Was observer blinded? | Options among no, yes and not reported |
| Drug effect on neuroanatomical assessment | Options qualifying effects among positive, negative, no effect, mixed (assessment), mixed (dosage), mixed (timing), mixed (timing of assessment), no stats, mixed (stats/no stats), mixed (assessment) + mixed (dosage), not reported, and mixed (assessment) + mixed (timing) |
| Drug effect on neuroanatomical assessment (details) | Details on the effects reported allowing to categorize the effects in the previous column |
| Conclusions and others | Drugs given to treat infections/pain ect. | Other drugs given to subjects according to the study protocol (e.g., pain relief plan, infection treatment or prophylaxis, anesthesia) |
| Conclusion of study | Conclusions as reported in the publication |
| Limitations | Limitations mentioned in the publication |
| Remarks/Comments | Personal remark or comments following extractions |
| Combination of drugs tested | Options among no, yes (drug of interest + drug of interest), and yes (drug of interest + drug not of interest) |
| Contradictions present in the results | Yes or no, flags contradictions between text and figures presented in a given manuscript |

Table S5.

Details on the bias classification for animal experiments.

|  |  |  |
| --- | --- | --- |
| **Domain of bias** | **Classified as “unclear risk of bias”** | **Classified “high risk of bias”** |
| Dose | No precise dose reported, including “high dose” | Not reported |
| Species | Subspecies not reported | Not reported |
| Route | - | Not reported |
| Level of injury | No precise level or range reported, including “cervical”, “mid-thoracic, ‘thoracic”, “lumbar-sacral” | Not reported |
| Treatment time | - | Not reported |
| Results | Mixed results due to lack of statistics reported, including "mixed (stats/no stats)", "mixed effects (assessment) + mixed (stats/no stats)", "no stats" | Not reported |
| Sample size | Sample size reported as range or bounded | Not reported |
| Sex | Mixed population (male/female) with ratio not reported | Not reported |
| Blinding | Not reported | No blinding applied |
| Age | Reported as “adult”, “young” with no precise age reported | Not reported |

Table S6.

Reported sample sizes by species in animal studies. “Other” include Yucatan miniature pigs (n=2) yellow eel Anguilla anguilla L. (n=1) SD: standard deviation; Q1: first quartile; Q3: third quartile

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Species** | **Mean** | **SD** | **Median** | **Q1** | **Q3** |
| cats | 26.53 | 16.50 | 24.00 | 16.50 | 31.00 |
| dogs | 33.43 | 25.13 | 26.00 | 22.00 | 32.00 |
| guinea pig | 21.00 | 7.55 | 20.00 | 17.00 | 24.50 |
| mice | 120.62 | 83.33 | 96.00 | 50.25 | 176.50 |
| other | 31.33 | 16.17 | 22.00 | 22.00 | 36.00 |
| rabbit | 69.36 | 50.57 | 47.00 | 28.50 | 133.00 |
| rats | 61.60 | 46.71 | 48.00 | 32.00 | 79.50 |

Table S7.

Bias assessment by animal experiment

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Experiment** | **Domain of bias** | | | | | | | | | | **Total bias score** |
| **Species** | **Sample size** | **Sex** | **Age** | **Level of injury** | **Dose** | **Treatment time** | **Route** | **Results** | **Blinding** |
| Pinzon et al. (2008, minocycline) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Sharp et al (2013, ibuprofen) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Liu et al (2015, omega 3) | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Bimbova et al (2018, atorvastatin) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Liu et al (2017, omega 3) | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Yang et al (2016, niacin) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Jiang et al (2004, methylprednisolone) | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Halt et al (1992, ethanol + isoflurane) | 1 | 0 | **2** | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 5 |
| Halt et al (1992, ethanol + ketamine + pentobarbital) | 1 | 0 | **2** | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 5 |
| Durham-Lee et al (2011, amiloride) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Imai et al (2018, amiloride) | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Krisa et al (2012, amphetamine) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Hook et al (2011, morphine) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gao et al (2014, methylprednisolone) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Baiyila et al (2018, methylprednisolone) | 0 | 0 | **2** | 1 | 0 | 0 | **2** | 0 | 0 | 1 | 6 |
| Bilginer et al (2009, methylprednisolone) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Bilginer et al (2009, mycophenolate) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Bilginer et al (2009, methylprednisolone + mycophenolate) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Hong et al (2020, vitamin c) | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Martins et al (2018, dantrolene) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gao et al (2016, atorvastatin) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Déry et al (2009, atorvastatin) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Yeng et al (2016, estradiol) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Genovese et al (2005, melatonin) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | **2** | 0 | 1 | 5 |
| Pannu et al (2005, atorvastatin) | 0 | 1 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Nash et al (2002, methylprednisolone) | 0 | 0 | **2** | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Zhang et al (2015, azithromycin) | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Faden et al (1981, naloxone) | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Giulian et al (1990, dexamethasone) | 0 | 1 | **2** | **2** | 1 | 0 | 0 | 0 | 0 | 1 | 7 |
| Salzman et al (1991, cyproheptadine) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Siriphorn et al (2012, estradiol) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Mohammadshirazi et al (2019, lithium) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Rabchevsky et al (2002, methylprednisolone sodium succinate) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Borgens et al (2001, polyethylene glycol) | 1 | 0 | **2** | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 6 |
| Ditor et al (2007, polyethylene glycol) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Ditor et al (2007, magnesium sulfate) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Ditor et al (2007, magnesium sulfate + polyethylene glycol) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Liu et al (2015, carvedilol) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Diaz-Ruiz et al (2011, dapsone) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Krityakiarana et al (2016, melatonin) | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Vanicky et al (2002, methylprednisolone sodium succinate) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Behrmann et al (1994, methylprednisolone sodium succinate) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Sadanaga et al (1989, chlorpromazine) | 0 | 1 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Gueye et al (2015, vitamin d) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Guth et al (1994, indomethacin) | 0 | 0 | 0 | **2** | 0 | 0 | **2** | 0 | **2** | 0 | 6 |
| Nazemi et al (2020, minocycline) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Lopez et al (2004, bupivacaine) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Namjoo et al (2018, estradiol) - rats - 10.1007/s11011-018-0220-8 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Çavus et al (2014, methylprednisolone) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Çavus et al (2014, acetylcysteine) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Çavus et al (2014, methylprednisolone + acetylcysteine) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Kang et al (2017, estradiol) | 0 | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 1 | 3 |
| Baltin et al (2021, methylprednisolone sodium succinate) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 1 | 3 |
| Chen et al (2018, methylprednisolone) | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 3 |
| Caliskan et al (2016, etomidate) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Caliskan et al (2016, epoietin) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Caliskan et al (2016, etomidate + epoietin) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Cayli et al (2004, methylprednisolone) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Cayli et al (2004, melatonin) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Cayli et al (2004, methylprednisolone + melatonin) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Cayli et al (2004, ethanol) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Cetin et al (2006, methylprednisolone) | 0 | 0 | **2** | **2** | 0 | 0 | 0 | 0 | 0 | 1 | 5 |
| Cetin et al (2006, epoietin) | 0 | 0 | **2** | **2** | 0 | 0 | 0 | 0 | 0 | 1 | 5 |
| Cetin et al (2006, methylprednisolone + epoietin) | 0 | 0 | **2** | **2** | 0 | 0 | 0 | 0 | 0 | 1 | 5 |
| Ha et al. (2008, pregabalin) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Ha et al. (2008, methylprednisolone) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | **2** | 1 | 4 |
| Ha et al. (2008, minocycline) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | **2** | 1 | 4 |
| Aslan et al (2009, dexmedetomidine) | 0 | 0 | 1 | **2** | 0 | 0 | 0 | 0 | **2** | 0 | 5 |
| Aslan et al (2009, dantrolene) | 0 | 0 | 1 | **2** | 0 | 0 | **2** | 0 | 0 | 0 | 5 |
| Colón et al (2018, tamoxifen) | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Xu et al (2009, dexamethasone) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Saganová et al (2009, tacrolimus) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 1 | 3 |
| Fabela-Sánchez et al (2018, albumin) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Darvishi et al (2014, valproic acid) | 0 | 1 | 0 | **2** | 0 | 0 | 0 | 0 | 1 | 1 | 5 |
| Torres et al (2018, dantrolene) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Guo et al (2018, metformin) | 0 | 0 | 0 | **2** | 0 | 0 | **2** | 0 | 0 | 0 | 4 |
| Chio et al (2021, immune globulin) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Kopper et al (2019, azithromycin) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Afshary et al. (2020, minocycline) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Zhang et al. (2017, metformin) - rats - 10.1007/s12035-016-9895-1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Liu et al. (2017, lithium) | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Jin et al. (2021, buspirone) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Jin et al. (2021, fluoxetine) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Brandoli et al. (2001, dexamethasone) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Faden et al (1984, naloxone) | 0 | 0 | **2** | **2** | **2** | 0 | 0 | 0 | 0 | 0 | 6 |
| Hashimoto et al. (1991, naloxone) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Winkler et al (1994, naloxone) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 1 | 3 |
| Faden et al (1983, naloxone) - cats | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Faden et al (1983, naloxone) - rats | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 1 | 0 | 3 |
| Faden et al (1983, naloxone) - rabbit | 0 | 0 | **2** | **2** | 1 | 0 | 0 | 0 | 1 | 0 | 6 |
| Chen et al. (2020, ezetimibe) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Oslau et al (2014, selegiline) | 0 | 1 | 0 | **2** | 0 | 0 | 0 | 0 | 1 | 1 | 5 |
| Salem et al. (2017, methylprednisolone sodium succinate) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Salem et al. (2017, vitamin c) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Salem et al. (2017, methylprednisolone sodium succinate + vitamin c) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Abdanipour et al. (2012, valproic acid) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Teixeira et al. (2018, methylprednisolone) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Tong et al. (2018, lithium) | 0 | 1 | 0 | 1 | **2** | 0 | 0 | 0 | 0 | 1 | 5 |
| Karatas et al. (2015, carvedilol) | 0 | 0 | **2** | **2** | 0 | **2** | **2** | **2** | 0 | 1 | 11 |
| Papa et al. (2016, minocycline) | 0 | 1 | **2** | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 5 |
| Pourheydar et al. (2018, ubiquinone) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 1 | 3 |
| Pourheydar et al. (2018, vitamin c) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 1 | 3 |
| Wang et al. (2017, minocycline) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Wang et al. (2019, minocycline) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Khoshsirat et al. (2018, methylprednisolone) | 0 | 0 | 0 | 1 | 0 | 0 | **2** | **2** | 0 | 0 | 5 |
| Fee et al. (2007, progesterone) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | **2** | 0 | 0 | 2 |
| Ritz et al. (2008, estradiol) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Means et al. (1981, methylprednisolone sodium succinate) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Holtz et al. (1990, methylprednisolone) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 1 | 1 | 4 |
| Korkmaz et al. (2015, montelukast) | 0 | 0 | 0 | **2** | 1 | 0 | 0 | **2** | 0 | 0 | 5 |
| Haghighi et al. (1987, naloxone) | 0 | 0 | **2** | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 4 |
| Arias (1985, naloxone) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 1 | 3 |
| Ross et al. (1993, methylprednisolone) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Gerber et al. (1980, phenytoin) | 0 | 0 | **2** | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 4 |
| Gerber et al. (1980, dexamethasone) | 0 | 0 | **2** | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 4 |
| Silva et al. (2008, prednisone) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Pan et al. (2006, tacrolimus) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Liu et al. (2017, methylprednisolone) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 1 | 3 |
| Liu et al. (2017, methotrexate) | 0 | 0 | 0 | **2** | 0 | 0 | **2** | 0 | 0 | 1 | 5 |
| Liu et al. (2017, methylprednisolone + methotrexate) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 1 | 3 |
| Ahmad et al. (2016, minocycline) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Ahmad et al. (2016, tacrolimus) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Ahmad et al. (2016, minocycline + tacrolimus) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Meng et al. (2011, methylprednisolone) | 0 | 1 | **2** | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 5 |
| Shen et al. (2019, levocarnitine) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Cristante et al. (2013, fluoxetine) | 0 | 0 | 0 | 0 | 0 | 0 | **2** | 0 | 1 | 0 | 3 |
| Zhou et al. (2016, calcitriol) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Nantwi et al. (1998, theophylline) | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 4 |
| Genovese et al. (2007, dexamethasone) - mice - 10.1111/j.1600-079X.2007.00454.x | 1 | 0 | **2** | **2** | 0 | 0 | 0 | 0 | 0 | 1 | 6 |
| Genovese et al. (2007, melatonin) | 1 | 0 | **2** | **2** | 0 | 0 | 0 | 0 | 0 | 1 | 6 |
| Genovese et al. (2007, dexamethasone + melatonin) | 1 | 0 | **2** | **2** | 0 | 0 | 0 | 0 | 0 | 1 | 6 |
| Farsi et al. (2015, methylprednisolone) | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Farsi et al. (2015, magnesium sulfate) | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Farsi et al. (2015, methylprednisolone + magnesium sulfate) | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Yin et al. (2013, methylprednisolone) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Lu et al. (2016, methylprednisolone) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Li et al. (2016, methylprednisolone) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Hou et al. (2015, celecoxib) | 0 | 0 | 0 | 0 | 0 | 0 | **2** | 0 | 0 | 1 | 3 |
| Qinxuan et al. (2020, dexamethasone + estrogen) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Qinxuan et al. (2020, dexamethasone) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Letaif et al. (2015, estradiol) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hains et al. (2004, phenytoin) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Mann et al. (2008, epoetin) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Mann et al. (2008, darbepoetin) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Liao et al. (2014, methylprednisolone) | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 3 |
| Li et al. (2019, methylprednisolone) | 0 | 0 | 0 | 0 | 0 | 0 | **2** | **2** | 0 | 1 | 5 |
| Wu et al. (2019, methylprednisolone) | 0 | 0 | 0 | 1 | 0 | 0 | **2** | 0 | 0 | 0 | 3 |
| Rong et al. (2018, methotrexate) | 0 | 0 | 0 | 0 | 0 | 0 | **2** | 0 | 0 | 1 | 3 |
| Wong et al. (2012, amphetamine) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lima et al. (2020, citalopram) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Li et al. (2014, methylprednisolone) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Chen et al. (2014, vitamin c e) | 0 | 0 | 0 | 1 | 0 | 0 | **2** | 0 | 0 | 0 | 3 |
| Akdemir et al. (1993, methylprednisolone) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Genovese et al. (2008, montelukast) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Chen et al. (2018, plasma) | 0 | 1 | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 3 |
| Chen et al. (2018, platelets) | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Kim et al. (2004, methylprednisolone) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Mbori et al. (2016, methylprednisolone) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Wiseman et al. (2009, methylprednisolone) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 2 |
| Wiseman et al. (2009, magnesium) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Wiseman et al. (2009, magnesium + methylprednisolone) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 2 |
| Ates et al. (2007, mexiletine) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 3 |
| Ates et al. (2007, phenytoin) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 3 |
| Serarslan et al. (2010, methylprednisolone) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 1 | 3 |
| Serarslan et al. (2010, tadalafil) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 1 | 3 |
| Hara et al. (2000, methylprednisolone sodium succinate) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Zendedel et al. (2018, estradiol) | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Braughler et al. (1987, methylprednisolone sodium succinate) | 0 | 0 | **2** | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Robertson et al. (1986, thiopental) | 0 | 0 | **2** | **2** | 1 | 0 | 0 | 0 | 0 | 1 | 6 |
| Robertson et al. (1986, magnesium sulfate) | 0 | 0 | **2** | **2** | 1 | 0 | 0 | 0 | 0 | 1 | 6 |
| Robertson et al. (1986, lidocaine) | 0 | 0 | **2** | **2** | 1 | 0 | 0 | 0 | 0 | 1 | 6 |
| Robertson et al. (1986, naloxone) | 0 | 0 | **2** | **2** | 1 | 0 | 0 | 0 | 0 | 1 | 6 |
| Robertson et al. (1986, thiopental + naloxone) | 0 | 0 | **2** | **2** | 1 | 0 | 0 | 0 | 0 | 1 | 6 |
| Kobrine et al. (1984, lidocaine) | 1 | 0 | **2** | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 6 |
| Hallenbeck et al. (1983, naloxone) | 0 | 0 | **2** | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 4 |
| Watanabe et al. (2012, minocycline) | 0 | 0 | **2** | **2** | 1 | 0 | 0 | 0 | 0 | 0 | 5 |
| Yücel et al. (2006, methylprednisolone) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Gürkan et al. (2020, methylprednisolone) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 1 | 1 | 4 |
| Schwartz et al. (2001, phenytoin) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Tator et al. (1983, liothyronine) | 0 | 0 | 0 | **2** | 0 | 0 | **2** | 0 | 0 | 0 | 4 |
| Young et al. (1982, methylprednisolone sodium succinate) | 1 | 0 | **2** | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 6 |
| Saganova et al. (2008, minocycline) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 1 | 3 |
| Rivlin et al. (1979, epinephrine) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Rivlin et al. (1979, epinephrine + nitroprusside) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Zhang et al. (2020, methylprednisolone) | 0 | 0 | 0 | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 2 |
| Zhang et al. (2020, metformin) | 0 | 0 | 0 | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 2 |
| Genovese et al. (2007, dexamethasone) - mice - 10.1016/j.neuroscience.2007.06.059 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Wu et al. (2017, sevoflurane) | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 3 |
| Lee et al. (2016, fluoxetine + vitamin c) | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| de Figueiredo et al. (2018, tramadol) | 0 | 0 | 0 | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 2 |
| Vasconcelos et al. (2016, magnesium chloride + polyethylene glycol) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Miranpuri et al. (2017, folic acid) | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Gül et al. (2005, methylprednisolone) | 0 | 0 | **2** | **2** | 0 | 0 | 0 | 0 | 1 | 1 | 6 |
| Gül et al. (2005, melatonin) | 0 | 0 | **2** | **2** | 0 | 0 | 0 | 0 | 1 | 1 | 6 |
| Fu et al. (2007, naproxen) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Fu et al. (2007, ibuprofen) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Cheng et al. (2016, estradiol) | 0 | 0 | 0 | **2** | 0 | 0 | **2** | 0 | 0 | 0 | 4 |
| Hu et al. (2012, estradiol) | 0 | 1 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Sun et al. (2020, gabapentin) | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| McCreedy et al. (2018, diclofenac) | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Tajkey et al. (2015, ceftriaxone) | 0 | 0 | 0 | 0 | **2** | 0 | **2** | 0 | 0 | 1 | 5 |
| Zheng et al. (2011, heparin) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Nguyen et al. (2012, immune globulin) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Ueno et al. (2011, minocycline) | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Wang et al. (2009, ibuprofen) - rats | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Wang et al. (2009, naproxen) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Wang et al. (2009, ibuprofen) - mice | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Ozkunt et al. (2017, methylprednisolone) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 2 |
| Ozkunt et al. (2017, epoetin) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 2 |
| Zakeri et al. (2014, lithium) | 0 | 1 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Teng et al. (2004, minocycline) | 0 | 1 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Wu et al. (2010, methylprednisolone) | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Huang et al. (2009, epoetin) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 1 | 3 |
| Lee et al. (2003, minocycline) | 0 | 1 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Lin et al. (2016, estradiol) | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 2 |
| Faden et al. (1981, naloxone) | 1 | 0 | **2** | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 4 |
| Holtz et al. (1991, methylprednisolone) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | **2** | 0 | 1 | 5 |
| Gorio et al. (2007, methylprednisolone sodium succinate) | 0 | 1 | **2** | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 4 |
| Ravikumar et al. (2005, nicotine) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Know et al. (2009, methylprednisolone) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Know et al. (2009, polyethylene glycol) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Know et al. (2009, magnesium sulfate) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Know et al. (2009, magnesium sulfate + polyethylene glycol) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Know et al. (2009, magnesium chloride + polyethylene glycol) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Know et al. (2009, methylprednisolone + magnesium chloride + polyethylene glycol) | 0 | 0 | 0 | **2** | 0 | **2** | 0 | 0 | 0 | 0 | 4 |
| Kachadroka et al. (2010, estradiol) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Roman et al. (2011, polyethylene glycol) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 |
| Bu et al. (2018, estradiol) | 0 | 0 | **2** | 0 | 0 | 0 | **2** | 0 | 1 | 1 | 6 |
| Fakhri et al. (2020, melatonin) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Hook et al. (2009, morphine sulfate) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Garcia-Ovejero et al. (2014, progesterone) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Erol et al. (2016, methylprednisolone) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 1 | 3 |
| Erol et al. (2016, topiramate) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 1 | 3 |
| Streijger et al. (2016, magnesium chloride + polyethylene glycol) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 1 | 3 |
| Streijger et al. (2016, magnesium sulfate) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 1 | 3 |
| Ji et al. (2005, methylprednisolone) | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Doyle et al. (2004, levodopa) | 0 | 0 | **2** | **2** | **2** | 0 | 0 | 0 | 1 | 1 | 8 |
| Ibarra et al. (2004, methylprednisolone sodium succinate) | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Kuroiwa et al. (2014, amiloride) | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Wells et al. (2003, methylprednisolone) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Wells et al. (2003, minocycline) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Guizar-Sahagun et al. (2009, methylprednisolone sodium succinate) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Guizar-Sahagun et al. (2009, melatonin) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Lee et al. (2010, minocycline) | 0 | 0 | **2** | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 4 |
| Lee et al. (2010, simvastatin) | 0 | 0 | **2** | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 4 |
| Zeman et al. (2009, oxandrolone) | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Cole et al. (1989, fentanyl + nitrous oxide ) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 1 | 0 | 3 |
| Cole et al. (1989, fentanyl + nitrous oxide + naloxone) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 1 | 0 | 3 |
| Kuchner et al. (2000, dexamethasone) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Luo et al. (2013, methylprednisolone) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Thomas et al. (1999, progesterone) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Stewart et al. (2019, folic acid) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stewart et al. (2019, nitrous oxide) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stewart et al. (2019, folic acid + nitrous oxide) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gok et al. (2007, methylprednisolone) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Dinc et al. (2013, methylprednisolone) | 0 | 0 | 0 | **2** | 0 | 0 | **2** | 0 | 1 | 1 | 6 |
| Lee et al. (2010, magnesium) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 1 | 3 |
| Sonmez et al. (2013, minocycline) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Cuzzocrea et al. (2008, estradiol) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 3 |
| Ren et al. (2017, polyethylene glycol) | 1 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 1 | 1 | 5 |
| Faden et al. (1984, dexamethasone) | 0 | 0 | **2** | **2** | 0 | 0 | 0 | **2** | 0 | 0 | 6 |
| Faden et al. (1984, methylprednisolone) | 0 | 0 | **2** | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 4 |
| Xu et al. (2019, melatonin) | 0 | **2** | **2** | **2** | 0 | 0 | 0 | 0 | 1 | 0 | 7 |
| Li et al. (2019, melatonin) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Yang et al. (2020, melatonin) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Piao et al. (2014, melatonin) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Zhang et al. (2019, melatonin) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Shen et al. (2017, melatonin) | 0 | 1 | 0 | 1 | 0 | 0 | **2** | 0 | 0 | 0 | 4 |
| Esposito et al. (2009, melatonin) | 1 | 0 | **2** | **2** | 0 | 0 | 0 | **2** | 0 | 1 | 8 |
| Jing et al. (2019, melatonin) | 0 | 0 | 0 | 1 | 0 | 0 | **2** | 0 | 0 | 0 | 3 |
| Fee et al. (2010, melatonin) | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Jeffrey-Gauthier et al. (2018, buspirone) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 1 | 3 |
| Holtz et al. (1989, naloxone) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 1 | 3 |
| Park et al. (2012, melatonin) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Ates et al. (2006, methylprednisolone) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Ates et al. (2006, ethanol) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Yingli et al. (2014, melatonin) | 0 | 0 | 0 | 1 | 0 | 0 | **2** | 0 | 0 | 1 | 4 |
| Yune et al. (2007, minocycline) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Yune et al. (2007, methylprednisolone) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Zhang et al. (2017, metformin) - rats - 10.1111/jcmm.13235 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Park et al. (2014, hydralazine) | 0 | 1 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 1 | 4 |
| Stirling et al. (2004, minocycline) | 0 | 0 | **2** | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Weaver et al. (2005, methylprednisolone) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Moutaery et al. (2000, aluminum) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| de Mesquita Coutinho et al. (2016, tacrolimus) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | **2** | 0 | 1 | 4 |
| Takami et al. (2002, methylprednisolone) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Chikawa et al. (2001, methylprednisolone) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Aceves et al. (2019, morphine) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Aceves et al. (2019, minocycline) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Aceves et al. (2019, morphine + minocycline) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Woller et al. (2014, morphine) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| de la Torre Valdovino et al. (2016, tamoxifen) | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 3 |
| Guo et al. (2015, acetylcysteine) | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 4 |
| Black et al. (1991, naloxone) | 0 | 0 | 1 | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Black et al. (1986, naloxone) - rats - 10.1227/00006123-198612000-00004 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black et al. (1986, naloxone) - rats - 10.1227/00006123-198612000-00005 | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Wang et al. (2020, metformin) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 1 | 0 | 3 |
| Lin et al. (2019, methylprednisolone) | 0 | 1 | 0 | 0 | 0 | **2** | 0 | 0 | 1 | 0 | 4 |
| Lin et al. (2019, methylprednisolone sodium succinate) | 0 | 1 | 0 | 0 | 0 | **2** | 0 | 0 | 1 | 0 | 4 |
| Koyanagi, Tator (1997, methylprednisolone) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 1 | 3 |
| Hook et al. (2017, morphine) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Wu et al. (2016, botulinum toxin) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 2 |
| Guth et al. (1994, indomethacin) | 0 | 0 | 0 | **2** | 0 | 0 | **2** | 0 | 0 | 0 | 4 |
| Lee et al. (2012, fluoxetine) | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Gao et al. (2020, melatonin) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Gorio et al. (2005, methylprednisolone sodium succinate) | 0 | 1 | **2** | 1 | 0 | 0 | **2** | 0 | 0 | 0 | 6 |
| Scali et al. (2013, fluoxetine) | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Dixit et al. (2018, clonidine) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Zhang et al. (2014, methylprednisolone sodium succinate) | 0 | 0 | **2** | **2** | 0 | **2** | **2** | **2** | 1 | 1 | 12 |
| Nazli et al. (2015, atorvastatin) | 0 | 0 | **2** | **2** | 1 | 0 | 0 | 0 | 0 | 0 | 5 |
| Li et al. (2014, atorvastatin) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Bharne et al. (2013, methylprednisolone) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Cayli et al. (2006, etomidate + methylprednisolone) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Cong, Chen (2016, dexamethasone) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Tan et al. (2015, methylprednisolone) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Cakir et al. (2003, acetylcysteine) | 0 | 0 | **2** | **2** | 1 | 0 | 0 | **2** | 0 | 1 | 8 |
| Gao et al. (2015, simvastatin) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Hou et al. (2016, methylprednisolone) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Wang et al. (2014, methylprednisolone) | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Sozbilen et al. (2018, methylprednisolone) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Yilmaz et al. (2015, clopidogrel) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Chen et al. (2015, methylprednisolone) | 0 | **2** | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 4 |
| Ok et al. (2012, methylprednisolone) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 2 |
| Kazanci et al. (2017, methylprednisolone + pregabalin) | 0 | 0 | **2** | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 5 |
| Kahveci et al. (2014, methylprednisolone + rosuvastatin) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Xian-Hui et al. (2016, methylprednisolone) | 0 | 0 | 0 | 1 | 0 | 1 | 0 | **2** | 0 | 0 | 4 |
| Kouhzaei et al. (2013, polyethylene glycol) | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 3 |
| Aceves et al. (2016, morphine) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Guizar-Sahagun et al. (2005, methylprednisolone sodium succinate) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| De La Torre et al. (1975, mannitol) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 1 | 1 | 4 |
| De La Torre et al. (1975, dexamethasone) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 1 | 1 | 4 |
| Yates et al. (2014, methylprednisolone) | 0 | 1 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 1 | 4 |
| Flamm et al. (1982, naloxone) | 0 | 0 | **2** | **2** | 0 | 0 | 0 | 0 | 1 | 1 | 6 |
| Wallace, Tator (1986, naloxone) - rats - 10.1227/00006123-198604000-00006 | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 1 | 3 |
| Wallace, Tator (1986, naloxone) - rats - 10.1227/00006123-198610000-00001 | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 1 | 3 |
| Cho et al. (2010, glucosamine) | 0 | 0 | 0 | 1 | 1 | **2** | 0 | 0 | 0 | 1 | 5 |
| Zadeh-Ardabili et al. (2017, vitamin e) | 0 | 0 | 0 | 0 | 0 | 0 | **2** | 0 | 0 | 1 | 3 |
| Gok et al. (2009, albumin) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Gok et al. (2009, immune globulin) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Khajoueinejad et al. (2019, calcitriol) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lim et al. (2013, omega 3) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Popovich et al. (2012, glibenclamide) | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Pukos, McTigue (2020, tamoxifen) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Durham-Lee et al. (2012, amiloride) | 0 | 1 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 1 | 4 |
| Perez-Espejo et al. (1996, methylprednisolone) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 1 | 0 | 3 |
| Patel et al. (2017, pioglitazone) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 1 | 3 |
| Nash et al. (2002, methylprednisolone) | 0 | 0 | **2** | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 4 |
| Lankhorst et al. (2000, methylprednisolone) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Liu et al. (2010, carbidopa levodopa) | 0 | 0 | 0 | 1 | 0 | 0 | **2** | 0 | 0 | 1 | 4 |
| Yang et al. (2020, glutamine) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pannu et al. (2007, atorvastatin) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Mann et al. (2010, atorvastatin) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Mann et al. (2010, simvastatin) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| King et al. (2006, omega 3) - rats - 10.1523/JNEUROSCI.5539-05.2006 - alpha-linolenic acid (AHA) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| King et al. (2006, omega 3) - rats - 10.1523/JNEUROSCI.5539-05.2006 - docosahexaenoic acid (DHA) | 0 | 0 | 0 | 1 | **2** | 0 | 0 | 0 | 0 | 1 | 4 |
| Fujimoto et al. (2000, melatonin) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Schiaveto-de-Souza et al. (2013, melatonin) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 1 | 3 |
| Karami et al. (2013, ketoprofen) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 1 | 3 |
| Tan et al. (2020, estrogen) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Wang et al. (2015, propofol) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Zhang et al. (2020, mannitol) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Yates et al. (2009, modafinil) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Iwasa et al. (1989, vitamin e) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 1 | 3 |
| Sengelaub et al. (2018, estradiol) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Sengelaub et al. (2018, testosterone) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Sengelaub et al. (2018, estradiol + testosterone) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Patel et al. (2014, acetylcysteine) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 1 | 3 |
| Osuna-Carrasco et al. (2016, tamoxifen) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Ren et al. (2019, polyethylene glycol) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 1 | 3 |
| Kaptanoglu et al. (2005, methylprednisolone) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Kaptanoglu et al. (2005, mexiletine) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Xing et al (2016, morphine) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Mu et al (2000, methylprednisolone) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Kazama et al (2001, pentobarbital) | 0 | 0 | **2** | **2** | 1 | 0 | 0 | 0 | 0 | 0 | 5 |
| Genovese et al (2007, dexamethasone) | 0 | **2** | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 4 |
| Pan et al (2013, tacrolimus) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Pereira et al (2009, methylprednisolone sodium succinate) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Cain et al (2007, albumin) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Liang et al (2019, simvastatin) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Liang et al (2019, ezetimibe + simvastatin) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Gao et al (2016, simvastatin) | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Han et al (2012, simvastatin) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Han et al (2011, simvastatin) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Han et al (2020, sitagliptin) | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 |
| He et al (2016, propofol) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Holmberg et al (2008, simvastatin) | 0 | 1 | 0 | 1 | 0 | 1 | **2** | 0 | 0 | 1 | 6 |
| Zhang et al (2018, lithium) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Tedeshi et al (2016, pregabalin) | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Kim et al (2017, lithium) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sanli et al (2012, methylprednisolone sodium succinate) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Salimi et al (2020, ceftriaxone) | 0 | 0 | 0 | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 2 |
| Salimi et al (2020, acetylcysteine) | 0 | 0 | 0 | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 2 |
| Salimi et al (2020, ceftriaxone + acetylcysteine) | 0 | 0 | 0 | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 2 |
| Ni et al (2018, estrogen) | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Xiao Jianru et al (1998, naloxone) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | **2** | 0 | 1 | 5 |
| Baffour et al (1995, methylprednisolone sodium succinate) | 0 | 0 | 1 | **2** | 0 | 0 | 0 | 0 | 1 | 0 | 4 |
| Qi et al (2017, methylprednisolone) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Yune et al (2004, estradiol) | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Nacar et al (2014, polyethylene glycol) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 1 | 0 | 3 |
| Nacar et al (2014, atorvastatin) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Baptiste et al (2009, polyethylene glycol) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Mallei et al (2005, prednisolone) | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Madsen et al (1998, tacrolimus) | 0 | 1 | **2** | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 5 |
| Colón et al (2016, tamoxifen) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Mosquera et al (2014, estradiol) | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Mosquera et al (2014, tamoxifen) | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Tian et al (2009, tamoxifen) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Kitchen et al (2020, trifluoperazine) | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Namjoo et al (2018, estradiol) - rats - 10.1002/jcb.27361 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Borgens et al (2002, polyethylene glycol) | 1 | 0 | **2** | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 4 |
| Hao et al (1991, naltrexone) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 1 | 3 |
| Ruhollah Hosseini et al (2017, dexamethasone) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Pedram et al (2018, meloxicam) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sharma et al (2004, methylprednisolone sodium succinate) | 0 | 0 | 1 | **2** | 1 | 0 | 0 | **2** | 1 | 1 | 8 |
| Sharma et al (2004, dexamethasone) | 0 | 0 | 1 | **2** | 1 | 0 | 0 | **2** | 1 | 1 | 8 |
| Guptarak et al (2014, tamoxifen) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Kermani et al (2016, acetylsalicylic acid) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Sayin et al (2013, methylprednisolone sodium succinate) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Baysefer et al (2003, mannitol) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 1 | 3 |
| Farooque et al (1994, methylprednisolone sodium succinate) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 1 | 3 |
| Golding et al (2006, glutamine) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Abdanipour et al (2019, lithium) | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Charn et al (2011, minocycline) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Gul et al (2010, methylprednisolone) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | **2** | 1 | 4 |
| Gul et al (2010, dexmedetomidine) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | **2** | 1 | 4 |
| Lang-Lazdunski et al (2001, tacrolimus) | 0 | 0 | 0 | **2** | 1 | 0 | 0 | 0 | 0 | 1 | 4 |
| Rosado et al (2014, methylprednisolone sodium succinate) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Rosado et al (2014, dantrolene) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Rosado et al (2014, methylprednisolone sodium succinate + dantrolene) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Boran et al (2005, methylprednisolone) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Boran et al (2005, epoetin) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Hook et al (2007, morphine sulfate) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Simpson et al (1991, nifedipine) | 0 | 0 | **2** | **2** | 1 | 0 | 0 | 0 | 0 | 1 | 6 |
| Simpson et al (1991, indomethacin) | 0 | 0 | **2** | **2** | 1 | 0 | 0 | 0 | 0 | 1 | 6 |
| He et al (2017, lithium) | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 4 |
| Almad et al (2011, fenofibrate) | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| McTigue et al (2007, pioglitazone) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Ko et al (2006, minocycline) | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Çelik et al (2015, vitamin d) | 0 | 0 | **2** | **2** | 0 | 0 | 0 | 0 | 1 | 1 | 6 |
| Park et al (2007, pioglitazone) | 0 | 1 | **2** | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 4 |
| Afhami et al (2016, estradiol) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Gezici et al (2017, methotrexate) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Narin et al (2017, topiramate) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gensel et al (2012, topiramate) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Yoshizaki et al (2019, heparin) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Arias (1987, naloxone) | 0 | 1 | 0 | **2** | 0 | 0 | 0 | 0 | 1 | 1 | 5 |
| Arias (1987, dexamethasone) | 0 | 1 | 0 | **2** | 0 | 0 | 0 | 0 | 1 | 1 | 5 |
| Naftchi et al (1991, methylprednisolone sodium succinate + aminocaproic acid) | 0 | 0 | **2** | **2** | 0 | 0 | 0 | 0 | **2** | 1 | 7 |
| Romero-Ramírez et al (2020, methylprednisolone) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 |
| Zhang et al (2009, tacrolimus) | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 1 | 3 |
| Zhang et al (2014, methylprednisolone) | 0 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Rabinowitz et al (2008, methylprednisolone) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Penas et al (2011, valproic acid) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Chu et al (2015, valproic acid) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Lee et al (2012, valproic acid) | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Lu et al (2013, valproic acid) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Lv et al (2012, valproic acid) | 0 | 1 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Lv et al (2011, valproic acid) | 0 | 1 | 0 | **2** | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Hao et al (2013, valproic acid) | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Wang et al (2020, valproic acid) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Li et al (2019, zinc) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Lin et al (2020, zinc) - mice - 10.1016/j.neulet.2020.135263 | 0 | 1 | 0 | 0 | 0 | 0 | **2** | 0 | 0 | 0 | 3 |
| Li et al (2020, zinc) | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Lin et al (2020, zinc) - mice - 10.1111/cns.13460 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |